Gray Zone Lymphoma: Better Treated Like Hodgkin Lymphoma or Mediastinal Large B-Cell
ROBUST: lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell
(22,24) Finally, false-positive results can occur when a B-cell
population emerges as a dominant clone in RLH.
A retrospective analysis was performed on 106 patients who were diagnosed with CD20-positive B-cell
non-Hodgkin's lymphoma according to the World Health Organization classification for pathological diagnosis, between January 2010 and April 2017; these patients were administered rituximab-containing chemotherapy, and they completed the follow-up (19).
epitope prediction aims to facilitate B-cell
epitope identification with the practical purpose of replacing the antigen for antibody production or for carrying structurefunction studies.
Kymriah became the first CAR-T cell therapy to receive regulatory approval when it was approved by the FDA in August 2017 for the treatment of patients up to 25 years of age with B-cell
precursor ALL that is refractory or in second or later relapse.
Immunohistochemically, IVLBCL is positive for B-cell
markers with variable aberrant expression of CD5.
Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell
lymphoma: a therapeutic dilemma.
Results: We found that miR-155 expression levels differentiate lymphoma entities from normal subjects (p [less than or equal to] 0.001) and its expression fold changes distinguish B-cell
lymphoma subtypes from each other's (p<0.05).
Keywords: Chronic lymphocytic leukemia, familial form, monoclonal B-cell
It remains controversial about the role of B-cell
subsets in obesity and T2D.
Treatment of B-cell
NHL typically relies upon multiagent cytotoxic chemotherapy (e.g., cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP]), tailored to the specific subtype of NHL and certain patient characteristics.